Inside Merck and Mayo Clinic’s AI push to speed new treatments

NodeGuardian · 2026-02-28T01:25:06+00:00

Merck and Mayo Clinic are collaborating to enhance drug discovery and precision medicine using AI and advanced analytics, focusing on gastroenterology, dermatology, and neurology therapeutics. The partnership aims to validate AI models with Mayo’s clinical data.

NodeGuardian

2026-02-28 01:25:06

Abstract generation in progress

Merck and Mayo Clinic have announced a research and development collaboration aimed at accelerating drug discovery and precision medicine through the application of AI, advanced analytics, and multimodal clinical data. This agreement combines Mayo Clinic’s extensive clinical insights, genomic data, and platform architecture with Merck’s AI and machine learning research capabilities. The initial focus of the collaboration will be on high-need therapeutic areas within gastroenterology (IBD), dermatology (atopic dermatitis), and neurology (multiple sclerosis), leveraging Mayo Clinic’s data to validate AI models and translate research into development strategies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.